Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 5 | 1 |
| List of Figures | 5 | 1 |
| Introduction | 6 | 1 |
| Global Markets Direct Report Coverage | 6 | 1 |
| Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) Overview | 7 | 1 |
| Therapeutics Development | 8 | 4 |
| Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) Products under Development by Stage of Development | 8 | 1 |
| Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) Products under Development by Therapy Area | 9 | 1 |
| Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) Products under Development by Indication | 10 | 2 |
| Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) Pipeline Products Glance | 12 | 2 |
| Late Stage Products | 12 | 1 |
| Early Stage Products | 13 | 1 |
| Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) Products under Development by Companies | 14 | 3 |
| Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) Therapeutics Assessment | 17 | 6 |
| Assessment by Monotherapy/Combination Products | 17 | 1 |
| Assessment by Mechanism of Action | 18 | 1 |
| Assessment by Route of Administration | 19 | 2 |
| Assessment by Molecule Type | 21 | 2 |
| Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) Companies Involved in Therapeutics Development | 23 | 8 |
| Antisense Therapeutics Limited | 23 | 1 |
| Atox Bio Ltd. | 24 | 1 |
| Biogen, Inc. | 25 | 1 |
| BioMAS Ltd. | 26 | 1 |
| Daiichi Sankyo Company, Limited | 27 | 1 |
| EA Pharma Co Ltd | 28 | 1 |
| Protagonist Therapeutics Inc. | 29 | 1 |
| Takeda Pharmaceutical Company Limited | 30 | 1 |
| Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) Drug Profiles | 31 | 26 |
| AB-103 Drug Profile | 31 | 3 |
| AS-101 Drug Profile | 34 | 2 |
| ATL-1102 Drug Profile | 36 | 5 |
| carotegrast Drug Profile | 41 | 2 |
| natalizumab Drug Profile | 43 | 4 |
| PTG-100 Drug Profile | 47 | 2 |
| Small Molecule to Antagonize Integrin Alpha4 and Beta7 for Inflammatory Bowel Disease Drug Profile | 49 | 1 |
| Small Molecule to Inhibit VLA-4 for Asthma Drug Profile | 50 | 1 |
| Small Molecules to Antagonize Integrin Alpha4 and Integrin Beta7 for Inflammatory Bowel Disease Drug Profile | 51 | 1 |
| vedolizumab Drug Profile | 52 | 5 |
| Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) Dormant Projects | 57 | 5 |
| Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) Discontinued Products | 62 | 1 |
| Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) Featured News &Press Releases | 63 | 16 |
| Jun 01, 2016: Antisense provides update on ATL1102 clinical trials | 63 | 1 |
| May 31, 2016: Biogen Receives Positive CHMP Opinion for TYSABRI (Natalizumab) Use in Highly Active RRMS Patients with Inadequate Response to Prior MS Therapy | 63 | 1 |
| May 26, 2016: Elan Pharma International Withdraw an application for a change to the marketing authorisation for Tysabri (natalizumab) | 64 | 1 |
| May 24, 2016: Takeda Presents Analyses From Vedolizumab Data in Ulcerative Colitis at 2016 Digestive Disease Week Annual Meeting | 65 | 1 |
| May 17, 2016: Protagonist Therapeutics to Present New Data on PTG-100 at Digestive Disease Week 2016 | 66 | 1 |
| Apr 12, 2016: Biogen to Present Data on TYSABRI (Natalizumab) at 2016 AAN Annual Meeting | 66 | 1 |
| Mar 19, 2016: New Data Presented at European Crohn's and Colitis Organisation Scientific Meeting on Efficacy of Long-Term Vedolizumab Treatment | 67 | 1 |
| Feb 26, 2016: EMA confirms recommendations to minimise risk of brain infection PML with Tysabri | 68 | 3 |
| Feb 12, 2016: Updated recommendations to minimise the risk of the rare brain infection PML with Tysabri | 71 | 1 |
| Jan 15, 2016: Pharmacovigilance Risk Assessment Committee (PRAC) provides update on ongoing referral on Tysabri | 72 | 1 |
| Jan 08, 2016: Protagonist Therapeutics Initiates Phase 1 Study with Oral Peptide PTG-100 | 73 | 1 |
| Dec 07, 2015: Atox Bio Enrolls First Patient in Phase 3 Study of Potential Treatment for Necrotizing Soft Tissue Infection (Flesh Eating Bacteria) | 74 | 1 |
| Oct 21, 2015: Biogen Reports Top-Line Results from Phase 3 Study Evaluating Natalizumab in Secondary Progressive MS | 74 | 1 |
| Oct 19, 2015: Takeda Presents Vedolizumab Data at the 2015 American College of Gastroenterology Annual Meeting and United European Gastroenterology Week | 75 | 2 |
| Oct 12, 2015: Antisense Therapeutics Provides ATL1102 Early Access Program Update | 77 | 2 |
| Appendix | 79 | 2 |
| Methodology | 79 | 1 |
| Coverage | 79 | 1 |
| Secondary Research | 79 | 1 |
| Primary Research | 79 | 1 |
| Expert Panel Validation | 79 | 1 |
| Contact Us | 79 | 1 |
| Disclaimer | 80 | 1 |